Improved plasma lipids and body weight in overweight/obese patients with type III hyperlipoproteinemia after 4 weeks on a low glycemic diet

2009 ◽  
Vol 28 (2) ◽  
pp. 213-215 ◽  
Author(s):  
Kjetil Retterstøl ◽  
Camilla Bæck Hennig ◽  
Per Ole Iversen
Keyword(s):  
Body Weight ◽  
Plasma Lipids ◽  
Obese Patients ◽  
Type Iii ◽  
Type Iii Hyperlipoproteinemia

Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia

Metabolism ◽  
1985 ◽  
Vol 34 (10) ◽  
pp. 978-981 ◽  
Author(s):  
Byron J. Hoogwerf ◽  
Jeffrey R. Peters ◽  
Ivan D. Frantz ◽  
Donald B. Hunninghake
Keyword(s):  
Plasma Lipids ◽  
Type Iii ◽  
Type Iii Hyperlipoproteinemia ◽  
Lipids And Lipoproteins

Hand-assisted laparoscopic nephrectomy in morbidly obese patients

2020 ◽  
Vol 99 (6) ◽  
pp. 271-276
Keyword(s):  
Body Weight ◽  
Surgical Technique ◽  
Blood Loss ◽  
Hospital Stay ◽  
Kidney Cancer ◽  
The Body ◽  
Laparoscopic Nephrectomy ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Morbid Obese

Introduction: Prevalence of obesity is 30 % in the Czech Republic and is expected to increase further in the future. This disease complicates surgical procedures but also the postoperative period. The aim of our paper is to present the surgical technique called hand-assisted laparoscopic nephrectomy (HALS), used in surgical management of kidney cancer in morbid obese patients with BMI >40 kg/m2. Methods: The basic cohort of seven patients with BMI >40 undergoing HALS nephrectomy was retrospectively evaluated. Demographic data were analyzed (age, gender, body weight, height, BMI and comorbidities). The perioperative course (surgery time, blood loss, ICU time, hospital stay and early complications), tumor characteristics (histology, TNM classification, tumor size, removed kidney size) and postoperative follow-up were evaluated. Results: The patient age was 38−67 years; the cohort included 2 females and 5 males, the body weight was 117−155 kg and the BMI was 40.3−501 kg/m2. Surgery time was 73−98 minutes, blood loss was 20−450 ml, and hospital stay was 5−7 days; incisional hernia occurred in one patient. Kidney cancer was confirmed in all cases, 48–110 mm in diameter, and the largest removed specimen size was 210×140×130 mm. One patient died just 9 months after the surgery because of metastatic disease; the tumor-free period in the other patients currently varies between 1 and 5 years. Conclusion: HALS nephrectomy seems to be a suitable and safe surgical technique in complicated patients like these morbid obese patients. HALS nephrectomy provides acceptable surgical and oncological results.

scholarly journals Effect of Mixed Nuts on Body Weight and Composition, and Gut Microbiome (P08-054-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Shih Lung Woo ◽  
Dina Ben-Nissan ◽  
Zahra Ezzat-Zadeh ◽  
Jieping Yang ◽  
Lijun Zhang ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Composition ◽  
Body Weight ◽  
Gut Microbiome ◽  
Plasma Lipids ◽  
Plasma Lipid ◽  
Healthy Weight ◽  
Weight Changes ◽  
Fecal Microbiome ◽  
Tree Nuts

Abstract Objectives This study was designed to assess the effects of mixed nut consumption on body weight and composition, and gut microbiome in obese individuals. Primary outcome was change in body weight and composition. Secondary outcomes include gut microbiome composition, inflammatory markers, and plasma lipids. Methods The reported results are from an interim analysis (n = 50) of a randomized, placebo controlled, parallel study. Total enrollment target is 154 overweight/obese subjects (BMI 27–35 kg/m2). Participants were randomly assigned to consume either 1.5oz mixed tree nuts or pretzels with equal calorie content daily for 24 weeks. The study included a 12-week weight loss phase (500 kcal per day less than total daily energy expenditure), followed by a 12-week weight maintenance phase. Body composition, fasting blood, and stool samples were collected at baseline, week 12 and 24. Body composition, and vitals were analyzed, whereas plasma lipid profile, fecal microbiome, and microbiome metabolites analysis is still pending. Results At week 12, subjects from both the pretzel (n = 15, 10 dropouts; P = 0.009) and nut group (n = 22, 3 dropouts; P = 0.038) lost significant amount of weight. The trend of weight changes did not differ between groups (P = 0.530). Subjects from both groups were able to sustain weight loss through 24 weeks (pretzel: 81.43 ± 3.85 kg at baseline vs. 79.43 ± 4.08 kg at week 24, P = 0.028; nut: 84.26 ± 3.78 kg at baseline vs. 82.38 ± 3.72 kg at week 24, P = 0.026). At week 12, fat mass in both groups was significantly decreased (pretzel: P = 0.002; nut: P = 0.012). The trend of fat changes did not differ between groups (P = 0.547). Subjects from both groups were able to sustain fat loss through 24 weeks (pretzel: 30.84 ± 1.75 kg at baseline vs. 29.25 ± 2.12 kg at week 24, P = 0.024; nut: 31.51 ± 1.56 kg vs 30.21 ± 1.81 kg at week 24, P = 0.04). Muscle mass, and blood pressure were not significantly different between both groups. Conclusions Our data suggested that tree nuts could be consumed as part of a healthy weight loss meal plan without concern of causing weight gain. Further analysis of the remaining samples is needed to confirm results. Due to higher dropouts in the pretzel group, future intention-to-treat analysis is also needed to eliminate bias. Funding Sources This study is supported by the International Tree Nut Council.

Assessing Safety and Efficacy of Lean Body Weight-Based intravenous Heparin Dosing in Obese and Morbidly Obese Patients

CHEST Journal ◽  
2015 ◽  
Vol 148 (4) ◽  
pp. 1010A ◽  
Author(s):  
Rachel Park ◽  
Scott Chelemer ◽  
Jason Varghese ◽  
Cheryl Leddy ◽  
Lewis Rose
Keyword(s):  
Body Weight ◽  
Lean Body Weight ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Safety And Efficacy ◽  
Intravenous Heparin

scholarly journals IV fosphenytoin in obese patients

2016 ◽  
Vol 7 (1) ◽  
pp. 45-52 ◽  
Author(s):  
Sarah L. Clark ◽  
Megan R. Leloux ◽  
Ross A. Dierkhising ◽  
Gregory D. Cascino ◽  
Sara E. Hocker
Keyword(s):  
Body Weight ◽  
Adverse Events ◽  
Vital Signs ◽  
Drug Distribution ◽  
Retrospective Chart Review ◽  
Current Method ◽  
Liver Function Tests ◽  
Excess Body Weight ◽  
Obese Patients ◽  
Bonferroni Adjustment

AbstractBackground:Previous studies evaluated the disposition of IV phenytoin loading doses and found that obese patients had increased drug distribution into excess body weight, larger volumes of distribution, and longer half-lives when compared to their nonobese counterparts. We assess the safety and efficacy of fosphenytoin loading doses in patients with different body mass indices (BMIs).Methods:A retrospective chart review was conducted in 410 patients who received fosphenytoin. Patients were divided into 2 groups: BMI <30 (nonobese) and BMI ≥30 (obese). Patient demographics, fosphenytoin dose administered in mg/kg body weight, renal and liver function tests, fosphenytoin drug levels, and pre- and post-fosphenytoin administration vital signs were collected to assess for adverse events. Necessity of additional antiepileptic loading doses was used as a surrogate for clinical efficacy.Results:The median dose of fosphenytoin administered was 19 mg/kg (interquartile range 15–20). The most frequently encountered adverse event was hypotension, which occurred in 39% of the cohort. Using a Bonferroni adjustment for multiple comparisons, there were no differences in adverse events between the 2 groups. The need for additional antiepileptic loading doses was not different between the 2 groups (p = 0.07).Conclusions:The incidence of adverse events and the need for repeat loading antiepileptic medications was similar between the 2 groups. From our findings, the patients in our study did not receive empiric loading dose adjustments and the current method of loading fosphenytoin achieves similar outcomes, regardless of the patient's BMI.

scholarly journals POS0358 EVALUATION OF THE EFFECT OF mTOR EXPRESSION ON THE CLINICAL MANIFESTATIONS OF KNEE OSTEOARTHRITIS IN OBESE AND NORMAL WEIGHT PATIENTS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 409.2-409
Author(s):  
E. Strebkova ◽  
E. Tchetina ◽  
L. Alekseeva
Keyword(s):  
Body Weight ◽  
Knee Pain ◽  
Mammalian Target Of Rapamycin ◽  
Clinical Manifestations ◽  
Normal Weight ◽  
Womac Pain ◽  
Obese Patients ◽  
Normal Body ◽  
Knee Oa ◽  
Normal Body Weight

Background:Currently, a large number of molecular biological and genetic markers are known to be involved in the development of osteoarthritis (OA). The mammalian target of rapamycin (mTOR) signaling pathway is responsible for chondrocyte proliferation, cartilage matrix production, and cell growth. OA is characterized by increased mTOR synthesis, which is accompanied by an increase in proliferative activity and destruction of chondrocytes. Obesity is an important factor in the progression of knee OA. The study of mTOR expression in patients with OA and obesity is an urgent task in the development of personalized OA therapy.Objectives:To determine the expression of mTOR in patients with knee OA in combination with obesity and normal body weight. To evaluate the effect of mTOR on the clinical manifestations of OA in patients with different body mass index (BMI).Methods:The study included 73 female patients aged 45-65 y.o. with Kellgren-Lawrence stage II-III knee OA. The patients were divided into 2 groups: group 1 (n=50) with obesity (BMI > 30 kg / cm2) and group 2 (n=23) with normal or increased body weight (BMI < 30 kg/cm2). The average age of patients with obesity is 56.5 ± 5.87 years, without obesity - 58.7 ± 5.43 years. Clinical manifestations were evaluated by a WOMAС. RNA was isolated from the patients ‘ blood samples, which was used to determine the expression of mTOR.Results:Patients with knee OA with and without obesity did not differ in age. OA develops at an earlier age in obese patients, than in non-obese patients (p < 0.001). Patients from 1 group had a high BMI > 30 kg/m2 at the onset of OA. Obese patients had more severe knee OA is significantly more often detected: Kellgren-Lawrence stage III was determined in 10% of obese patients and in 4.35% - without obesity (p < 0.001). Significantly higher values of the WOMAC index pain, stiffness, joint functional failure, and total WOMAC were observed in obese patients (p = 0.006, p = 0.039, p = 0.037, and p = 0.014, respectively). Obese patients had higher VAS pain scores (p < 0.05) compared to patients with a lower BMI. Obese patients had a higher mTOR expression (p < 0.05) of 8.02±8.62, compared to non-obese patients. High mTOR expression was associated with VAS knee pain (r=0.78; p < 0.05) and WOMAC pain (r=0.89; p<0.05) in obese patients (Table 1).Table 1.Correlation of m-TORParametersmTOR (1 group, n=50)mTOR (2 group, n=23)Body weightр > 0,05р > 0,05Pain (VAS)r=0,78; р<0,05p = 0,07; r = 0,45Pain (WOMAC)r=0,89; р<0,05р > 0,05Total WOMACр > 0,05р > 0,05Conclusion:Our study showed that patients with obesity and knee OA have higher rates of mTOR expression, compared to patients with normal body weight. High mTOR expression correlates with the severity of knee pain in obese patients. Thus, the evaluation of mTOR expression in obese patients and knee OA plays an important role in predicting the severity of clinical manifestations of OA, and may influence the choice of personalized therapy tactics for such patients.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document